These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

719 related articles for article (PubMed ID: 20823406)

  • 1. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.
    Harousseau JL; Attal M; Avet-Loiseau H; Marit G; Caillot D; Mohty M; Lenain P; Hulin C; Facon T; Casassus P; Michallet M; Maisonneuve H; Benboubker L; Maloisel F; Petillon MO; Webb I; Mathiot C; Moreau P
    J Clin Oncol; 2010 Oct; 28(30):4621-9. PubMed ID: 20823406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
    Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
    J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.
    Harousseau JL; Attal M; Leleu X; Troncy J; Pegourie B; Stoppa AM; Hulin C; Benboubker L; Fuzibet JG; Renaud M; Moreau P; Avet-Loiseau H
    Haematologica; 2006 Nov; 91(11):1498-505. PubMed ID: 17043025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
    Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
    J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma.
    Kobayashi T; Kuroda J; Fuchida S; Murakami S; Hatsuse M; Okano A; Iwai T; Tsutsumi Y; Kamitsuji Y; Akaogi T; Kawata-Iida E; Shimizu D; Uchiyama H; Matsumoto Y; Horiike S; Nakao M; Takahashi R; Kaneko H; Uoshima N; Kobayashi Y; Shimazaki C; Taniwaki M
    Intern Med; 2013; 52(9):961-8. PubMed ID: 23648714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
    Rosiñol L; Oriol A; Mateos MV; Sureda A; García-Sánchez P; Gutiérrez N; Alegre A; Lahuerta JJ; de la Rubia J; Herrero C; Liu X; Van de Velde H; San Miguel J; Bladé J
    J Clin Oncol; 2007 Oct; 25(28):4452-8. PubMed ID: 17785704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
    Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
    J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
    Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD
    Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial.
    Rifkin RM; Gregory SA; Mohrbacher A; Hussein MA
    Cancer; 2006 Feb; 106(4):848-58. PubMed ID: 16404741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
    Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
    Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
    Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma.
    Bensinger WI; Jagannath S; Vescio R; Camacho E; Wolf J; Irwin D; Capo G; McKinley M; Potts P; Vesole DH; Mazumder A; Crowley J; Becker P; Hilger J; Durie BG
    Br J Haematol; 2010 Feb; 148(4):562-8. PubMed ID: 19919652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.